FY2025 Earnings Estimate for CRL Issued By William Blair

Charles River Laboratories International, Inc. (NYSE:CRLFree Report) – Analysts at William Blair reduced their FY2025 earnings estimates for shares of Charles River Laboratories International in a research note issued to investors on Wednesday, January 15th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $9.40 for the year, down from their previous estimate of $10.59. William Blair has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share.

Charles River Laboratories International (NYSE:CRLGet Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the firm earned $2.72 EPS. The business’s quarterly revenue was down 1.6% compared to the same quarter last year.

CRL has been the topic of a number of other research reports. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Citigroup cut shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Finally, Bank of America reduced their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $209.00.

Get Our Latest Research Report on CRL

Charles River Laboratories International Stock Performance

NYSE CRL opened at $169.84 on Monday. The company has a market capitalization of $8.69 billion, a P/E ratio of 21.26, a P/E/G ratio of 5.75 and a beta of 1.38. The company has a fifty day moving average of $188.58 and a 200-day moving average of $197.93. Charles River Laboratories International has a 52-week low of $160.85 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Empirical Finance LLC lifted its position in Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares during the period. American Trust lifted its position in Charles River Laboratories International by 5.9% during the second quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 54 shares during the period. OLD National Bancorp IN lifted its position in Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after purchasing an additional 59 shares during the period. Fiduciary Financial Group LLC lifted its position in Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 63 shares during the period. Finally, Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.